Celgene’s QUAZAR AML-001 trial of CC-486 meets primary and key secondary endpoints
The study evaluated the efficacy and safety of investigational therapy CC-486 as maintenance therapy in patients with newly diagnosed acute myeloid leukemia (AML) who achieved first complete response